摘要
目的观察兰索拉唑联合瑞巴派特治疗慢性非萎缩性胃炎的临床疗效。方法 86例胃镜和取病理证实的慢性非萎缩性胃炎患者,随机分为甲组和乙组,分别治疗4周和8周,满疗程后观察临床症状、炎性因子、复查胃镜和病理变化。结果治疗后两组患者的临床症状、血生化指标及胃镜和病理结果均较治疗前明显改善,乙组疗效更显著,总有效率分别为88.37%和97.67%(Z=-2.44,P=0.015)。结论兰索拉唑联合瑞巴派特治疗慢性非萎缩性胃炎临床疗效确切,8周疗程效果更理想。
Objective To observe the clinical effect of lansoprazole combined with rebamipide on the treatment of chronic non-atrophic gastritis（CNAG）. Methods Eighty six patients with CNAG were collected and divided into group A and group B, all patients were received lansoprazole and rebamipide therapy, group A for 4 weeks, B group for 8 weeks. The clinical symptoms, inflammatory factor, gastroscopy and pathological changes were observed after the treatment. Results The clinical symptoms, serum inflammatory factor contents, gastroscopy and pathological results of patients were improved in two groups after treatment, the total effective rates were 88.37% and 97.67% （Z=-2.44,P=0.015） in group A and group B respectively, the better outcome occurred in group B. Conclusion The therapy of lansoprazole associated with rebarnipide had a good efficacy on CNAG, the long course of treatment has a better effect.
出处
《中国医药指南》
2013年第29期312-313,共2页
Guide of China Medicine
关键词
慢性非萎缩性胃炎
兰索拉唑
活检
C反应蛋白
Chronic non-atrophic gastritis
Lansoprazole
Biopsy
C reactive protein
